EORTC studies | ||||
Study | Response (percent) | MST (months) | ||
Mitoxantrone | 2.4 | 7.5 | ||
Epidoxorubicin | 13.5 | 8.9 | ||
Etoposide (IV) | 4.2 | 6.7 | ||
Etoposide (PO) | 7.3 | 8.7 | ||
Paclitaxel | 0 | 9.3 | ||
Poor prognostic factors in multivariate analysis | ||||
| Variable | MST (months) | ||
Performance status (PS) | Good (0) | 10.7 | ||
Poor (1-2) | 7.2 | |||
WBC count | High (>8.3) | 6 | ||
Low (<8.3) | 10.4 | |||
Hemoglobin difference* | High (>1 g/dL) | 7.3 | ||
Low (<1 g/dL) | 9.6 | |||
Histologic diagnosis | Definite | 9.8 | ||
Possible | 6 | |||
Sarcomatous subtype | Present | 5 | ||
Other subtype | 8.4-9.1 | |||
EORTC prognostic groups | ||||
Group characteristics | MST (months) | 1 yr OS | 2 yr OS | |
Low risk (prognostic score <1.27) | 10.8 | 40 percent | 14 percent | |
Equivalent to having 0-2 poor prognostic factors | ||||
High risk (prognostic score >1.27) | 5.5 | 12 percent | 0 percent | |
Equivalent to having three or more poor prognostic factors |
Do you want to add Medilib to your home screen?